Long-term regularly inhaled XXXX .

@entity748 @entity1 @entity3045 @entity565
Seventeen @entity748 @entity1 were allocated at random to one of two treatment regimens: prophylactic (10 @entity1 ), in which @entity3045 inhaler was used regularly in a dose of 200 micrograms 4-times daily; or symptomatic (7 @entity1 ), in which a placebo inhaler was used regularly as 2 actuations 4-times daily. In both regimens, an 'escape' @entity3045 inhaler was given to be used for symptomatic relief if and when needed. The study lasted 12 months, after a run-in period of 1 month to accustom @entity1 to the trial procedure. At the end of the year, 16 @entity1 transferred to the alternative regimen for a further 3 months. Both groups were well matched except that the group starting with the prophylactic regimen had more severe airways obstruction than the symptomatic group. @entity1 were assessed by daily scores of their @entity748 symptoms, twice daily PEFR measurements and the amount of anti- @entity748 medication used. Acute reversibility tests were performed every month at the clinic visits. @entity1 treated prophylactically had less seasonal variation in PEFR and generally lower symptom scores despite a lower mean PEFR. There was no evidence to suggest tolerance was developing either by acute reversibility tests or by an escalating use of symptomatic @entity3045 or other anti- @entity565 medication. The prophylactic use of @entity3045 seemed to provide a more stable control of @entity565 , offering potential benefit to @entity1 .
